The authors developed a mutation enhanced prognostic system consisting of adverse mutations including SF3B1, SRSF2, TP53, and U2AF1 in ET and SRSF2 in PV affecting OS, leukemia-free survival or myelofibrosis-free survival [186]. Here, SF3B1 is linked to myelofibrosis.